Posted by Michael Wonder on 14 Jun 2018
FDA approves Merck’s Keytruda (pembrolizumab) for treatment of refractory or relapsed primary mediastinal large B-cell lymphoma
13 June 2018 - Keytruda is the first anti-PD-1 therapy approved for adult and paediatric patients with refractory PMBCL or who have relapsed after two or more prior lines of therapy.
Merck today announced that the U.S. FDA has approved Keytruda, the company’s anti-PD-1 therapy, for the treatment of adult and paediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy. . This is the second indication for Keytruda for the treatment of a haematologic malignancy.
The approval was based on data from KEYNOTE-170, a multicenter, open-label, single-arm trial evaluating KEYTRUDA in 53 patients with relapsed or refractory PMBCL.
